본문으로 건너뛰기
← 뒤로

Comment on "Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma".

0/5 보강
Journal of the Formosan Medical Association = Taiwan yi zhi 📖 저널 OA 42.3% 2022: 0/3 OA 2023: 0/1 OA 2024: 2/3 OA 2025: 0/31 OA 2026: 39/50 OA 2022~2026 2025 Vol.124(10) p. 998-999
Retraction 확인
출처

Qu L, Li R, Li Y

이 논문을 인용하기

↓ .bib ↓ .ris
APA Qu L, Li R, Li Y (2025). Comment on "Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma".. Journal of the Formosan Medical Association = Taiwan yi zhi, 124(10), 998-999. https://doi.org/10.1016/j.jfma.2025.05.032
MLA Qu L, et al.. "Comment on "Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma".." Journal of the Formosan Medical Association = Taiwan yi zhi, vol. 124, no. 10, 2025, pp. 998-999.
PMID 40436728 ↗

같은 제1저자의 인용 많은 논문 (5)